CBT on Fatigue in Survivors of Hodgkin Lymphoma
Cognitive Behavioral Therapy (CBT) Web-based Intervention on Fatigue in Survivors of Hodgkin Lymphoma - a Pilot Study
Background: Cancer-related fatigue is one of the most common patient-reported impairments in survivors of Hodgkin lymphoma and is associated with adverse effects on psychological well-being and everyday life including family, work and social participation.
Methods: The investigators here present a bi-centric (Cologne and Leipzig) pilot-study for a web-based intervention (Cognitive Behavioral Therapy) on cancer-related fatigue. In detail, the investigators will conduct a non-randomized and non-controlled before-and-after study in a minimum of 20 survivors of Hodgkin lymphoma. Levels of fatigue and quality of life will be measured before the intervention (T0), post-intervention (T1) and at 3-months follow-up (T2).
Results: The investigators will provide information regarding the feasibility of the intervention (i.e., response rate, patient and therapist adherence, and patient satisfaction) and preliminary results on the efficacy of the program in reducing CRF and increasing levels of quality of life.
Aims: The results of this pilot-study will provide essential information to conduct a future randomized clinical trial to investigate the efficacy of this intervention in reducing cancer-related fatigue in survivors with Hodgkin lymphoma.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Concrete Aims: The investigators aim to conduct a a feasibility study, e.g., a pilot study before a randomized controlled trial can be planned in detail. This initial pilot-study is intended to test out the standard operating procedures, evaluate the feasibility, acceptance and adherence to the study protocol as well as preliminary efficacy of the web-based intervention for survivors of Hodgkin lymphoma. In detail, this study contains all preparation for conducting a trial, i.e., the translation, the adaptation and evaluation of the cognitive-behavioral web-based intervention manual from the original Dutch Version, the adaptation and implementation of all necessary technical and research-administrative requirements to successfully conduct the web-based randomized controlled trial and the evidence-based training of all study therapists including the implementation of therapists supervision. The investigators further assess adherence of the patients and therapists, the response rate and the patient satisfaction. Furthermore, preliminary efficacy of the intervention will be tested assessing levels of fatigue and quality of life at each measurement point.
Study Design: The design of this pilot web-based intervention on treating fatigue will be a non-randomised prospective non-controlled before-and-after study, in which observations will be made only in a patient group that receives the intervention. No control group will be recruited. Assessments will be conducted on the three measurement points: before the therapy (T0), after the intervention (T1) and 3 months after the intervention (T2).
Intervention: The internet-based cognitive behavioral therapy on postcancer fatigue includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months. The intervention will be specifically tailored to the individual needs of each patient: The therapy model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with Hodgkin lymphoma and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed. The intervention will consist of a maximum of eight treatment modules: aside from the six modules addressing the fatigue maintaining factor there is a module on goal formulation and realization of goals.
Recruitment: the recruitment will be realized on the basis of two ongoing trials of the German Hodgkin study group (HD 16- HD18) where fatigue of the patients is measured continuously.
Duration: The duration for patients will be 9 months (6 months intervention, 3 month-follow-up assessment). The duration of the whole study will be 18 months.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Cologne, Germania
- University Medical Center Cologne
-
-
Saxony
-
Leipzig, Saxony, Germania, 04103
- University Medical Center Leipzig
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- fluency in German language
- able to access the internet and use and follow a web-based Cognitive Behavioral intervention
- in complete remission after treatment for newly diagnosed HL without signs of relapse (no previous relapse)
- clinically relevant fatigue symptoms enduring at least 12 months after end of treatment (QLQ-C30 FA-12 ≥ 30 over at least two time points within the previous assessments in the course of the GHSG-trials)
- fatigue being related to HL and its treatment and interferes with usual functioning, i.e. fulfills the definition of CRF [1, 16].
Exclusion Criteria:
- Major communication difficulties
- severe cognitive impairment that would interfere with a patient's ability to give informed consent for research (indicated by the medical care team)
- Karnofsky Performance Status scale score < 70 predicting an expected survival of less than 6 months
- somatic co-morbidities that could explain the presence of severe fatigue (e.g. Chronic Obstructive Pulmonary Disease or heart failure) according to the hemato-oncologists examining the potential participant before inclusion for the study
- history of relapsed or refractory HL
- clinical symptoms which may indicate a relapse of HL
- current depressive disorder and related psychotropic or psychological treatment
- Currently receiving medical and/or psychological treatment for a psychiatric disorder, other than the use of an anti-depressant
- current treatment aimed at fatigue
- previous attempt to treat fatigue with behavioral psychological therapy
- pregnant or breastfeeding women
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Cognitive Behavioral Therapy for Treating Fatigue
This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
|
The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months. The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Tasso di risposta
Lasso di tempo: Il periodo di valutazione per questo risultato sarà dall'inizio del reclutamento fino all'inclusione dell'ultimo paziente, che sarà di circa 1 anno.
|
Gli investigatori valuteranno la quantità di pazienti ammissibili che sono disposti a partecipare allo studio rispetto alla quantità di pazienti che sono stati invitati a partecipare.
|
Il periodo di valutazione per questo risultato sarà dall'inizio del reclutamento fino all'inclusione dell'ultimo paziente, che sarà di circa 1 anno.
|
|
Aderenza del paziente
Lasso di tempo: Durante la fase di intervento per ogni paziente, che sarà di circa sei mesi.
|
L'adesione del paziente sarà valutata attraverso la documentazione degli abbandoni del paziente.
In dettaglio, documenteremo se i pazienti lasciano lo studio durante il trattamento (e se sì, in quale fase).
|
Durante la fase di intervento per ogni paziente, che sarà di circa sei mesi.
|
|
Soddisfazione del paziente
Lasso di tempo: Valutato una sola volta per ogni paziente, subito dopo che il paziente ha completato l'intervento.
|
Valutato da un questionario (Working Alliance Inventory - modulo rivisto rivisto).
Verrà presentato il punteggio totale dei 12 item, valutato su una scala Likert a cinque punti (da 12 a 60).
Valori più alti presentano maggiore soddisfazione.
|
Valutato una sola volta per ogni paziente, subito dopo che il paziente ha completato l'intervento.
|
|
Therapist adherence
Lasso di tempo: Assessed during the intervention phase for each patient, i.e., within about 6 six months.
|
Using information of the therapy protocols of each participant, it will be assessed if the treatment sessions were done according to the treatment protocol.
|
Assessed during the intervention phase for each patient, i.e., within about 6 six months.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Levels of fatigue 1
Lasso di tempo: Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
|
Assessed by a questionnaire, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Module Measuring Cancer-Related Fatigue (EORTC QLQ-FA12).
The questionnaire assesses the level of cancer-related fatigue.
The sum score across all 12 items, rated on a 4-point Likert scale, will be reported (total range: 12-48).
Higher values indicate higher levels of fatigue (i.e., higher values indicate a worse outcome).
|
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
|
|
Levels of fatigue 2
Lasso di tempo: Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
|
Levels of fatigue will additionally assessed by a second questionnaire, the Checklist Individual Strength - Subscale Fatigue Severity.
The scale assesses the level of cancer-related fatigue.
The sum score across all 8 items, rated on a 7-point Likert scale, will be presented (total range: 8 - 56).
Higher values indicate higher levels of fatigue (i.e., higher values indicate a worse outcome).
|
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
|
|
Global quality of life
Lasso di tempo: Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
|
Global quality of Life will be assessed by the European Organisation for Research and Treatment of Cancer (EORTC), Quality of Life-questionnaire (EORTC QLQ-C30).
Global quality of life is assessed in a 2-item subscale of the questionnaire, each rated on a 7-point-Likert scale (total range: 2-14).
According to the questionnaire manual, however, the sum score of the two items will be linear-transformed to a 0-100 scale, with higher values indicating higher levels of quality of life (i.e., higher values indicate a better outcome).
|
Assessed at three time points: before the intervention, immediately after the intervention and 3 months after the intervention
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Anja Mehnert, Prof. Dr., University of Leipzig
- Investigatore principale: Peter Borchmann, Prof. Dr., University of Cologne
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 933 000-146
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .